论文部分内容阅读
目的：探讨氨磺必利与阿立哌唑治疗首发精神分裂症的疗效及安全性。方法将124例首发精神分裂症患者按随机数字表分为两组，采用双盲、双模拟平行对照的方法分别口服氨磺必利和阿立哌唑治疗，观察8周。采用阳性与阴性症状量表、临床疗效总评量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表和临床疗效总评量表评分均较治疗前显著性下降（ P＜0．05或0．01）；治疗8周末氨磺必利组显效率63．3％、总有效率88．3％，阿立哌唑组分别为64．4％、91．5％，两组比较差异无显著性（χ2＝0．01、0．33，P＞0．05）。不良反应均较轻微，发生率比较差异无显著性（P＞0．05）。结论氨磺必利与阿立哌唑治疗首发精神分裂症疗效显著，总体疗效相当，起效快，安全性高，依从性好。“,”Objective To explore the efficacy and safety of amisulpride and aripi‐prazole in the treatment of first‐episode schizophrenia .Methods Using randomized ,double‐blind ,double‐dummy parallel controlled method 124 first‐episode schizophrenics were assigned to two groups taking o‐rally amisulpride and aripiprazole respectively for 8 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the PANSS and CGI scores of both groups lowered more significantly compared with pretreatment (P 0 .05) .Ad‐verse reactions were mild ,there were no group significant difference in incidence of adverse reaction (P>0 .05) .Conclusion Both amisulpride and aripiprazole have an equivalent evident effect in first‐episode schizophrenia ,take effect rapidly ,and have higher safety and better compliance .